Business Wire

BAE-SYSTEMS

Share
Sweden, Germany, United Kingdom Jointly Acquire 436 BAE Systems BvS10 All-Terrain Vehicles

Sweden, Germany, and the United Kingdom have reached an agreement with BAE Systems to purchase 436 BvS10 all-terrain vehicles. The joint procurement, worth $760 million, is in support of Arctic operations for the Collaborative All-Terrain Vehicle (CATV) program.

BAE Systems’ military all-terrain vehicles are designed for operations in the harshest and most remote environments and this agreement signals the Company’s position as the defense industry’s leader for these capabilities.

“We‘re seeing increased interest from numerous countries for the extreme mobility capabilities offered by the BvS10 and its unarmored sister vehicle, Beowulf,” said Tommy Gustafsson-Rask, managing director of BAE Systems Hägglunds, which manufactures the vehicles in Örnsköldsvik, Sweden. “Sweden, Germany, and the United Kingdom will be getting an excellent return on their investment in these highly capable vehicles for decades to come. This further demonstrates the strong relationship between BAE Systems and our customers to deliver these critical capabilities.”

The three-nation acquisition will deliver the 436 vehicles beginning in 2024, with 236 BvS10s going to the Swedish Defense Materiel Administration (FMV), 140 to the German Federal Ministry of Defence (BAAINBw), and 60 to the United Kingdom Ministry of Defence (MoD). The vehicles are based on the latest version of the BvS10 currently operated by Sweden, and will include variants for troop transport, logistics, medical evacuation, recovery, and command and control.

The CATV program includes a framework agreement that could lead to the purchase of more vehicles by the three nations, keeping the BvS10, the world’s leading all-terrain vehicle, in production for many years to come. Sweden is the lead nation and has established a joint procurement office to lead the effort with representatives from all three nations.

This acquisition follows Sweden’s order last year of an additional 127 BvS10 all-terrain vehicles for its existing fleet. In parallel to this agreement, Sweden is also procuring an additional 40 BvS10s in a separate contract valued at approximately $50 million.

The BvS10 and Beowulf are the world leaders when it comes to all-terrain solutions. Their articulated mobility systems provide optimal maneuverability across varying terrains so they can traverse snow, ice, rock, sand, mud or swamps, as well as steep mountain environments. The vehicles’ amphibious feature also allow them to swim in flooded areas or coastal waters.

The vehicles can deliver personnel and supplies to sustain strategic, tactical, and operational mobility.

BvS10’s unprecedented mobility is based on terrain accessible North Atlantic Treaty Organization (NATO) standards. Its modular design allows it to be reconfigured for varying missions and can be delivered in multiple variants that include carrying personnel, command and control, ambulance, vehicle repair and recovery, logistics support, situational awareness, and a weapons carrier with additional mortar capability.

BvS10 is currently operated by Austria, France, the Netherlands, Sweden, and the United Kingdom. BAE Systems’ Beowulf, the unarmored variant of the BvS10, won the U.S. Army’s competition for its Cold Weather All-Terrain Vehicle (CATV) program in August. The U.S. Army will receive 110 vehicles over a five-year period.

Issued by:
BAE Systems, Inc.
www.baesystems.com
@BAESystemsInc

For associated imagery, please visit: https://baesys.resourcespace.com/?c=16201&k=d788ec24d8

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221216005114/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye